NeuroDerm issued a new US patent for aqueous apomorphine covering concentrated subcutaneously delivered pharmaceutical compositions
![](/46/pdcnewsitem/04/19/29/neuroderm.png)
Company's ND0701 formulation intended for chronic therapy of Parkinson's disease and is developed for continuous subcutaneous administration by a small, low-volume, disposable patch-pump.
NeuroDerm has announced that the US Patent and Trademark Office has issued US Patent No. 9,381,249, which claims aqueous pharmaceutical compositions comprising apomorphine, and relates to the company’s ND0701 program. ND0701's formulation, containing concentrated apomorphine-base, is intended for chronic therapy of Parkinson's disease and is developed for continuous subcutaneous administration by a small, low-volume, disposable patch-pump. ND0701 has been shown in pre-clinical studies to have better local tolerability than commercially available, continuous, subcutaneously administered apomorphine-HCl. NeuroDerm is currently conducting a bioequivalence trial in the EU (Trial 101) comparing ND0701 with commercially available continuous, subcutaneously delivered apomorphine-HCl in its pursuit of a regulatory development route in the EU based on bioequivalence. The patent has an expiration date of 2033.
“ND0701 is an innovative, proprietary, concentrated apomorphine-base formulation resulting from NeuroDerm’s expertise in formulation chemistry,” said Oded S. Lieberman, NeuroDerm’s CEO. “This patent demonstrates our capabilities in developing novel, pharmaceutical formulations designed to enable and/or improve therapies for central nervous system diseases by continuous, subcutaneous drug administration. With the recently initiated ND0701 bioequivalence trial and potential to pursue an abbreviated regulatory pathway in the EU, we believe our novel formulation, designed for delivery by a small, convenient patch-pump, may be able to bring to Parkinson’s disease patients a much needed new treatment option.”
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance